THERAPY DOSSIER · th-a89ae9da5010

N-acetylheparin and aurin tricarboxylic acid (tested in separate arms)

Drug · N-acetylheparin and aurintricarboxylic acid (separate arms); complement/polyanionic inhibitors.

Evidence & regulatory context

Mechanism: N-acetylheparin and aurintricarboxylic acid (separate arms); complement/polyanionic inhibitors.
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31177985 ↗2019Reported benefit

Complement Inhibition Attenuates Early Erythrolysis in the Hematoma and Brain Injury in Aged Rats.

RatHaemorrhage/shockUnspecifiedFischer 344Malen = 109 aged rats used in total with 12 excluded (97 analysed).…Intracerebral, co-injected into the right basal ganglia with the autologous bloodN-acetylheparin 10 micrograms in 5 microlitres saline; auri…Given at the time of haemorrhage induction, co-injected with the blood

Model: Intracerebral haemorrhage induced by stereotaxic injection of 100 microlitres of autologous blood into the right basal ganglia (0.2 mm anterior, 5.5 mm ventral, 3.5 mm lateral to bregma) at 10 microlitres/min

Both complement inhibitors reduced early erythrolysis within the clot. N-acetylheparin lowered erythrolysis at day 1 (14.3+/-6.4% versus 20.9+/-6.1%, p<0.01) and day 3 (21.4+/-7.4% versus 30.9+/-8.7%, p<0.01), reduced perihaematomal iron at day 1 (24.1+/-9.7% versus 49.0+/-13.2%, p<0.01), reduced H…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…